Literature DB >> 9228944

Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.

W J Metzler, J Bajorath, W Fenderson, S Y Shaw, K L Constantine, J Naemura, G Leytze, R J Peach, T B Lavoie, L Mueller, P S Linsley.   

Abstract

The structure of human CTLA-4 reveals that residues Met 99, Tyr 100 and Tyr 104 of the M99YPPPY104 motif are adjacent to a patch of charged surface residues on the A'GFCC' face of the protein. Mutation of these residues, which are conserved in the CTLA-4/CD28 family, significantly reduces binding to CD80 and/or CD86, implicating this patch as a ligand binding site.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228944     DOI: 10.1038/nsb0797-527

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  27 in total

Review 1.  Recent advances in segmental isotope labeling of proteins: NMR applications to large proteins and glycoproteins.

Authors:  Lenka Skrisovska; Mario Schubert; Frédéric H-T Allain
Journal:  J Biomol NMR       Date:  2009-08-19       Impact factor: 2.835

2.  Glycan structure and serum half-life of recombinant CTLA4Ig, an immunosuppressive agent, expressed in suspension-cultured rice cells with coexpression of human β1,4-galactosyltransferase and human CTLA4Ig.

Authors:  Seung Hoon Kang; Hahn Sun Jung; Song Jae Lee; Cheon Ik Park; Sang Min Lim; Heajin Park; Byung Sun Kim; Kwang Heum Na; Gyeong Jin Han; Jae Woo Bae; Hyun Joo Park; Keuk Chan Bang; Byung Tae Park; Hye Seong Hwang; In-Soo Jung; Jae Il Kim; Doo Byung Oh; Dong Il Kim; Hirokazu Yagi; Koichi Kato; Dae Kyong Kim; Ha Hyung Kim
Journal:  Glycoconj J       Date:  2015-05-14       Impact factor: 2.916

3.  Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Authors:  Udupi A Ramagopal; Weifeng Liu; Sarah C Garrett-Thomson; Jeffrey B Bonanno; Qingrong Yan; Mohan Srinivasan; Susan C Wong; Alasdair Bell; Shilpa Mankikar; Vangipuram S Rangan; Shrikant Deshpande; Alan J Korman; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

4.  Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 molecules.

Authors:  Tadatsura Koshika; Carol Phelps; Jason Fang; Seung Eun Lee; Minoru Fujita; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

5.  Chemical cross-linking with thiol-cleavable reagents combined with differential mass spectrometric peptide mapping--a novel approach to assess intermolecular protein contacts.

Authors:  K L Bennett; M Kussmann; P Björk; M Godzwon; M Mikkelsen; P Sørensen; P Roepstorff
Journal:  Protein Sci       Date:  2000-08       Impact factor: 6.725

6.  Cell signaling, post-translational protein modifications and NMR spectroscopy.

Authors:  Francois-Xavier Theillet; Caroline Smet-Nocca; Stamatios Liokatis; Rossukon Thongwichian; Jonas Kosten; Mi-Kyung Yoon; Richard W Kriwacki; Isabelle Landrieu; Guy Lippens; Philipp Selenko
Journal:  J Biomol NMR       Date:  2012-09-26       Impact factor: 2.835

Review 7.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

Review 8.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.